Cochrane · systematic review · CD011721
Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta₂‐agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
Kew, KM, Dahri, K · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 1 · 14.3%High 4 · 57.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table 1
Population: adults with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbations requiring oral corticosteroids 48 weeks | OR 0.76 [0.57, 1.02] | 2 studies · 907 participants | Moderate Downgraded: imprecision |
Quality of life (AQLQ) | no estimate extracted | 2 studies · 907 participants | High |
Serious adverse events 49 weeks | OR 0.6 [0.24, 1.47] | 3 studies · 1197 participants | Low Downgraded: imprecision, indirectness |
Exacerbations requiring hospital admission 49 weeks | OR 0.68 [0.34, 1.38] | 3 studies · 1191 participants | Low Downgraded: imprecision, inconsistency, indirectness |
Lung function (change in trough FEV1 L) | no estimate extracted | 3 studies · 1191 participants | High |
Asthma control (ACQ) | no estimate extracted | 2 studies · 907 participants | High |
Any adverse events 49 weeks | OR 0.7 [0.52, 0.94] | 3 studies · 1197 participants | High |